Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making

Yagudina, R.; Kulikov, A.Yu.; Serpik, V.G.; Ugrekhelidze, D.T.

doi:10.1016/j.vhri.2017.07.006

Cited by 16 publications

(13 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The data used for model analysis were extracted from the tenders of the Ministry of Health (MOH) and the unit costs for services in its facilities. The choice of cost elements or variables used in the model relied on clinical trials that were conducted on these drugs in both the United States and Australia, mainly the PLATO clinical trial (Yagudina, et al, 2017). Following Orlewska and Mierzejewski (2004) our study depended on two scenarios in forecasting the BIA, baseline scenario which consisted of the analysis of the current state and the forecasting of the current state if the new procedure not implemented.…”

Section: Description Of the Sample And Modelsmentioning

confidence: 99%

A Framework for Developing a Model Structure of Budget Impact Analysis for New Health Care Interventions in Jordan

Massad¹,

Bakir²

2021

IJEFI

View full text Add to dashboard Cite

This paper assesses the impact of substituting clopidogrel with ticagelor to treat patients after an acute attack of Ischemic Heart Disease from the perspective of Jordanian MOH in its tenders, using Budget Impact Analysis (BIA). A multiple regression analysis used to estimate the elasticities associated of implementing the two treatments, and then Matlab used to compare the old and new treatments. The study recommends the gradually substitution of the new treatment using ticagelor because it achieves total cost savings of approximately 200,000 Jordanian dinars, and that the flexibility of the new treatment costs is less than in the case of the old treatment, which means that the increase in numbers of patients will lead to a lower increase in the total costs when using the new treatment.

show abstract

Section: Description Of the Sample And Modelsmentioning

confidence: 99%

A Framework for Developing a Model Structure of Budget Impact Analysis for New Health Care Interventions in Jordan

Massad¹,

Bakir²

2021

IJEFI

View full text Add to dashboard Cite

show abstract

“…[1][2][3][4][5][6] Of particular importance is this opportunity when conducting budget impact analysis. [7][8][9] Practice has shown that the pharmacoeconomic models that allow not only to analyze the impact budget, but also to form an application template for the exact volumes of drugs (DP) in kind, are most in demand by healthcare organizers, especially at the regional level of the healthcare system and for inpatient settings, necessary to meet the needs of a given number of patients. 10 The current situation reflects the trend towards a deeper immersion of the pharmacoeconomics in the process of organizing drug provision, in which pharmacoeconomic models should not provide an abstract assessment of drugs, but an assessment carried out taking into account the characteristics and limitations of specific drug provision programs or conditions for the provision of medical care.…”

Section: Introductionmentioning

confidence: 99%

“…Pharmacoeconomic calculations carried out at the federal level (with the exception of rare diseases and other cases with a minimal number of patients, for example, when a medicine is used in a narrow subgroup of patients) for the country as a whole, taking into account regional differences, initially present an average clinical and economic assessment of drugs; the interval of its possible deviations from the presented average value is set as part of the sensitivity analysis. [1][2][3][4][5][6][7][8][9][10][11][12][13][14][15] The implementation of the option to form an application in such models is impractical, since this process, within the framework of the current system for organizing drug provision, belongs to the authorities of the constituent entities of the state (on an outpatient basis) and medical institutions (on an inpatient basis). 16 Therefore, for decision-makers at the regional level of the healthcare system and at the level of individual medical institutions, comprehensive budget impact analysis models with the possibility of generating an application can be a useful tool.…”

Section: Introductionmentioning

confidence: 99%

Patient Flows, Patient Distribution Computations and Medicines Accounting in the Pharmacoeconomic Models Through Procurement Perspective

Yagudina

Kulikov

Serpik

et al. 2021

CEOR

View full text Add to dashboard Cite

Purpose Stimulating cost reduction of pharmaceutical companies to optimize the structure of distribution of patients by the level of treatment costs in various programs. Patients and Methods In this article, we rise up the issues of pharmacoeconomic modeling related to the description of the patient flows in the pharmacoeconomic model and methods to determining the course dose of drugs under the restriction of integer computations. We established two possible ways of distributing patients through treatment regimens in pharmacoeconomic models, also analyzed the effects of simultaneous and uniform entry of patients into the model. Also, we considered the limitations and possibilities of calculations based on the active substance and packaging, as well as the transition factor of the remainder of the drug in the next time period. Results A mathematical model of the analysis of the system assessment of patients by the level of risk of abandoning a healthy lifestyle in connection with the growing problems of the difficult-to-control process is developed. The use of a rational data convolution mode allowed us to obtain a criterion for the optimality of the process and a logical point of stability of the pharmaceutical company by rationally applying treatment methods according to established standards (percentage base). This approach makes it possible to influence the management of private clinics through clear ideas on the algorithms for prescribing drugs in each group of patients and their zoning in the vector recovery mode. Conclusion Initial data and sample size: 552 measurements of the intervals of changes in the subject’s indicators in seconds (smoothing and scaling the data to the level of the base (analytical) period or the final (barrier) period). Regular use of this approach makes it possible to reserve the resources of the body of a healthy and physically active person in a timely manner for a very reliable functioning of all body systems, taking into account the dosed intake of prescribed drugs and the conditions of comfortable (decent) maintenance of patients during the course of treatment according to the method chosen by the doctor.

show abstract

“…Healthcare consumers are also inclined to be more sensitive to medical treatments costs, whether they value more or less the information in reducing future health uncertainty [15]. In any case, considering the real potential of the new technologies to improve the healthcare system, a new approach is required, able to support decision-makers to modernize the pre-existing framework and to exploit new technologies in a more efficient, effective and sustainable way [2] while also protecting patients, spending resources more wisely, and fostering the "right" type of innovation in the future [3].Currently, cost effectiveness analysis is the most frequently used methodology [16] but, as far as it supports the allocation of resources [4], it suffers from theoretical limitations that make it inappropriate in many situations, leading to contraindications [17,18].In particular, technological innovation, as regards cost-containment measures, is an important factor for managing high and increasing health costs. In literature, the evidence suggests that enhanced health technologies generally increase rather than reduce healthcare expenditures.…”

mentioning

confidence: 99%

“…Currently, cost effectiveness analysis is the most frequently used methodology [16] but, as far as it supports the allocation of resources [4], it suffers from theoretical limitations that make it inappropriate in many situations, leading to contraindications [17,18].…”

mentioning

confidence: 99%

From Health Technology Assessment to Health Technology Sustainability

et al. 2018

View full text Add to dashboard Cite

This paper aims to propose a methodological lens to the assessment of technological innovations in healthcare based on the principles of social, economic, and political sustainability. Starting from the consideration of a lack of a unified interpretative framework of health technology assessment, using a content analysis of the relevant literature on the topic, we identified both the scientific perspectives adopted by the scholars and the most widely discussed topics. Consequently, the less explored scientific areas were framed, and, therefore, those more susceptible to further investigation came to light. The result is an overall picture which highlights the absence of unified and generally accepted approaches to evaluation, together with the lack of awareness on the fact that the multiplicity of methods adopted is essentially connected to the multiplicity of innovations, for each of which a method (or a set of methods) of preferable evaluation can be prefigured. Based on these observations, we propose a general reference framework for evaluation, based on the Viable Systems Approach (vSa), and a schematic outline of the connections between the complexity of innovations and the evaluation methodologies.Sustainability 2018, 10, 4748 2 of 22 other relates to the increasingly demanding policy makers and funders, who require greater evidence for new and existing therapies [6].Adopted primarily in the USA in the 1970s [7,8] and rapidly spread in Europe in the following decades, HTAs are currently being introduced in most countries of the world [3]. During the 1970s, the focus was to summarize the evidence concerning studies on the cost effectiveness of health interventions. Afterwards, at the end of the 1990s, HTA widened its focus from the evaluation of only large, expensive and machine-based technologies also to smaller technologies and healthcare, addressing broader issues (organizational, social implications, and ethics) [7]. Currently, the health technology assessment processes critically evaluate reimbursement submissions of pharmaceuticals, simple medical devices, and complex medical devices, such as hospital technologies [9], vaccines, procedures, health services, and public health interventions. Therefore, they are becoming an important tool to support health policy decisions in many countries [9].Nowadays, the importance of HTAs has increased further, also spreading in Central and Eastern European countries. HTA activities have a national focus associated with the Ministry of Health and, by influencing health policy documents of the European Commission, it seems likely that, in the future, the HTA will be institutionalized somehow as part of the EU's activities. The task of applying HTA techniques for the evaluation of new health technologies is devolved to the different government support bodies (e.g., NICE in the UK, IQWIG in Germany, and AGENAS in Italy).Thus, HTAs act to define a policy research approach that examines the short and long-term social, economic, and political consequences of the applicatio...

show abstract

Concept of Combining Cost-Effectiveness Analysis and Budget Impact Analysis in Health Care Decision-Making

Cited by 16 publications

References 8 publications

A Framework for Developing a Model Structure of Budget Impact Analysis for New Health Care Interventions in Jordan

A Framework for Developing a Model Structure of Budget Impact Analysis for New Health Care Interventions in Jordan

Patient Flows, Patient Distribution Computations and Medicines Accounting in the Pharmacoeconomic Models Through Procurement Perspective

From Health Technology Assessment to Health Technology Sustainability

Contact Info

Product

Resources

About